



## **Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day**

**May 23, 2023 10:30 AM EDT**

BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- [Verve Therapeutics](#), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat during the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day on Tuesday, May 30, 2023 at 4:10 p.m. ET.

A live webcast will be available in the investor section of the company's website at [www.vervetx.com](http://www.vervetx.com). The webcast will be archived for 30 days following the presentation.

### **About Verve Therapeutics**

Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company's initial three programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease, in order to durably reduce blood LDL-C levels. VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat atherosclerotic cardiovascular disease (ASCVD) patients not at goal on oral therapy. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and ultimately to treat patients with refractory hypercholesterolemia. For more information, please visit [www.VerveTx.com](http://www.VerveTx.com).

### **Investor Contact**

Jen Robinson  
Verve Therapeutics, Inc.  
[jrobinson@vervetx.com](mailto:jrobinson@vervetx.com)

### **Media Contact**

Ashlea Kosikowski  
1AB  
[ashlea@1abmedia.com](mailto:ashlea@1abmedia.com)